文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

一种用于预测前列腺特异性抗原(PSA)水平在4-20 ng/mL的患者患前列腺癌的、带有凝血标志物的列线图。

A nomogram with coagulation markers for prostate cancer prediction in patients with PSA levels of 4-20 ng/mL.

作者信息

Liu Feifan, Wang Jianyu, Song Yufeng, Wu Fei, Wu Haihu, Lyu Jiaju, Ning Hao

机构信息

Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, P.R. China.

Department of Urology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong Province, P.R. China.

出版信息

Future Oncol. 2025 Feb;21(4):463-471. doi: 10.1080/14796694.2024.2445499. Epub 2024 Dec 23.


DOI:10.1080/14796694.2024.2445499
PMID:39711215
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11812327/
Abstract

BACKGROUND: The global incidence of prostate cancer (PCa) is rising, necessitating improved diagnostic strategies. This study explores coagulation parameters' predictive value for clinically significant PCa (csPCa) and develops a nomogram. RESEARCH DESIGN AND METHODS: This study retrospectively analyzed data from 702 patients who underwent prostate biopsy at Shandong Provincial Hospital (SDPH) and 142 patients at Shandong Cancer Hospital and Institute (SDCHI). SDPH patients were randomly assigned at a 7:3 ratio for internal validation, while SDCHI data served as external validation. LASSO and logistic regression identified the best predictive factors for csPCa, which were used to construct a model. The model's efficacy was tested using AUC, calibration curves, and decision curve analysis. RESULTS: TPSA, age, D-dimer, prostate volume (PV), and digital rectal examination (DRE) were identified as independent risk factors for csPCa. A predictive model was constructed using a nomogram. The AUC for the training set was 0.841, for internal validation 0.809, and for external validation 0.814. Calibration and decision curves confirmed the model's clinical utility. CONCLUSIONS: The nomogram incorporating D-dimer, TPSA, age, PV, and DRE provides a highly accurate tool for assessing csPCa risk in individuals with PSA levels of 4-20 ng/mL, supporting personalized diagnostics and clinical decision-making.

摘要

背景:前列腺癌(PCa)的全球发病率正在上升,因此需要改进诊断策略。本研究探讨凝血参数对临床显著性前列腺癌(csPCa)的预测价值,并开发一种列线图。 研究设计与方法:本研究回顾性分析了山东省立医院(SDPH)702例接受前列腺活检患者以及山东省肿瘤医院暨山东省肿瘤防治研究院(SDCHI)142例患者的数据。SDPH患者按7:3的比例随机分配用于内部验证,而SDCHI的数据用作外部验证。LASSO和逻辑回归确定了csPCa的最佳预测因素,并用于构建模型。使用AUC、校准曲线和决策曲线分析对模型的有效性进行了测试。 结果:总前列腺特异性抗原(TPSA)、年龄、D-二聚体、前列腺体积(PV)和直肠指检(DRE)被确定为csPCa的独立危险因素。使用列线图构建了一个预测模型。训练集的AUC为0.841,内部验证为0.809,外部验证为0.814。校准曲线和决策曲线证实了该模型的临床实用性。 结论:包含D-二聚体、TPSA、年龄、PV和DRE的列线图为评估总前列腺特异性抗原水平在4-20 ng/mL的个体发生csPCa的风险提供了一种高度准确的工具,支持个性化诊断和临床决策。

相似文献

[1]
A nomogram with coagulation markers for prostate cancer prediction in patients with PSA levels of 4-20 ng/mL.

Future Oncol. 2025-2

[2]
Multicenter External Validation and Optimization of a Proposed Nomogram for Prostate-Specific Membrane Antigen PET/CT Accuracy in Biochemical Recurrence.

Prostate. 2025-8

[3]
A strategy to reduce unnecessary prostate biopsies in patients with tPSA >10 ng ml -1 and PI-RADS 1-3.

Asian J Androl. 2025-7-1

[4]
The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review.

Eur Urol. 2008-8

[5]
Diagnostic Performance of Prostate-specific Antigen Density for Detecting Clinically Significant Prostate Cancer in the Era of Magnetic Resonance Imaging: A Systematic Review and Meta-analysis.

Eur Urol Oncol. 2024-4

[6]
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.

Clin Orthop Relat Res. 2024-12-1

[7]
Development and Validation of a Predictive Model of Prostate Screening Compliance: A Nationwide Population-Based Study.

Prostate. 2025-5

[8]
A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA Trial.

J Urol. 2025-5

[9]
A novel nomogram for predicting osteoporosis with low back pain among the patients in Wenshan Zhuang and Miao Autonomous Prefecture of China.

Front Endocrinol (Lausanne). 2025-6-5

[10]
Are Current Survival Prediction Tools Useful When Treating Subsequent Skeletal-related Events From Bone Metastases?

Clin Orthop Relat Res. 2024-9-1

本文引用的文献

[1]
Periprostatic Adipose Tissue: A New Perspective for Diagnosing and Treating Prostate Cancer.

J Cancer. 2024-1-1

[2]
Based on PI-RADS v2.1 combining PHI and ADC values to guide prostate biopsy in patients with PSA 4-20 ng/mL.

Prostate. 2024-3

[3]
Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam.

Eur Urol. 2024-1

[4]
Development and internal validation of a nomogram predicting significant prostate cancer: Is it clinically applicable in low prevalent prostate cancer countries? A multicenter study.

Prostate. 2024-1

[5]
The Molecular Basis and Clinical Consequences of Chronic Inflammation in Prostatic Diseases: Prostatitis, Benign Prostatic Hyperplasia, and Prostate Cancer.

Cancers (Basel). 2023-6-8

[6]
Diagnostic Efficiency of Pan-Immune-Inflammation Value to Predict Prostate Cancer in Patients with Prostate-Specific Antigen between 4 and 20 ng/mL.

J Clin Med. 2023-1-19

[7]
Prebiopsy bpMRI and hematological parameter-based risk scoring model for predicting outcomes in biopsy-naive men with PSA 4-20 ng/mL.

Sci Rep. 2022-12-19

[8]
MRI determined prostate volume and the incidence of prostate cancer on MRI-fusion biopsy: a systemic review of reported data for the last 20 years.

Int Urol Nephrol. 2022-12

[9]
The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis.

Cancers (Basel). 2022-5-27

[10]
Modified Prostate Health Index Density Significantly Improves Clinically Significant Prostate Cancer (csPCa) Detection.

Front Oncol. 2022-4-7

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索